Novartis Bemused As NICE Says No Again To Migraine Drug Aimovig
Executive Summary
The Swiss major is evaluating whether or not there is a case to appeal after the cost watchdog said it is “very uncertain" whether the CGRP inhibitor is more clinically effective for migraine than Botox.